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Bacterial exotoxins and endotoxins both stimulate proinﬂammatory mediators but the contribution of each individual toxin in
the release of mediators causing lethal shock is incompletely understood. This study examines the cytokine response and lethality
of mice exposed to varying doses of staphylococcal enterotoxin B (SEB) or lipopolysaccharide (LPS) and their combinations. In
vivo, SEB alone induced moderate levels of IL-2 and MCP-1 and all mice survived even with a high dose of SEB (100 μg/mouse).
LPS (80 μg/mouse) caused 48% lethality and induced high levels of IL-6 and MCP-1. SEB induced low levels of TNFα,I L - 1 ,I F N γ,
MIP-2, and LPS synergized with SEB in the expression of these cytokines and that of IL-6 and MCP-1. Importantly, the synergistic
action of SEB and LPS resulted in lethal shock and hypothermia. ANOVA of cytokine levels by survival status of SEB-plus-LPS
groups revealed signiﬁcantly higher levels of TNFα, IL-6, MIP-2, and MCP-1 in nonsurvivors measured at 8 hours. Signiﬁcantly
higher levels of IFNγ and IL-2 were observed at 21 hours in nonsurvivors of toxic shock compared to those in survivors. Overall,
synergistic action of SEB and LPS resulted in higher and prolonged levels of these key cytokines leading to toxic shock.
1.Introduction
Bacterial exotoxins and endotoxins are among the most
common etiological agents that cause septic shock [1–3].
Although similar cytokines are released from host cells stim-
ulated with these structurally distinct bacterial products, the
stimulants act through distinct cell surface receptors on host
cells. Staphylococcal enterotoxin B (SEB) and structurally
related exotoxins are bacterial superantigens that potently
activate antigen-presenting cells by binding directly to major
histocompatibility complex (MHC) class II molecules [1, 4,
5]. These exotoxins also interact with speciﬁc Vβ regions
of the T cell antigen receptors resulting in polyclonal T cell
activation [6]. Interactions of superantigens with antigen-
presenting cells and T cells lead to massive proinﬂammatory
cytokine and chemokine release, causing clinical symptoms
that include fever, hypotension, and shock [1, 2, 4, 7, 8].
In contrast, lipopolysaccharide (LPS) from gram-
negative bacteria binds to a diﬀerent receptor on mono-
cytes/macrophages. An LPS-binding protein in serum ﬁrst
binds to LPS and facilitates its binding to cell surface protein
CD14 on monocytes/macrophages and other cells [9, 10].
The subsequent interaction of LPS/CD14 complex with Toll-
like receptor 4 on these cells initiates recruitment of intracel-
lularadaptorsanddownstreamsignalingpathwaysactivating
NFκB and results in hyperproduction of proinﬂammatory
cytokines and chemokines [10, 11]. High levels of these
mediators induce systemic inﬂammatory response, vascular
collapse, and shock [12].
In humans, either SEB or LPS alone can induce shock
as humans are very sensitive to these bacterial products
[2, 12, 13]. Current in vivo investigations on SEB-induced
pathogenesis have relied heavily on murine models of lethal
shock. However, mice are less susceptible (compared to
humans) to SEB due to the decreased aﬃnity of SEB to
m o u s eM H Cc l a s sI Im o l e c u l e s[ 14, 15] and enhancing
agents are used in addition to SEB [16–21]. Potentiating
agents such as LPS, D-galactosamine, or actinomycin D were
used to amplify the toxic eﬀects of SEB in vivo [18–21]. In
these various animal models, there is a strong correlation2 Mediators of Inﬂammation
between toxicity and increased serum levels of inﬂammatory
mediators, TNFα, IL-1, IL-6, and IFNγ [16–19]. However,
the contribution of each individual cytokine or chemokine
totoxicityhasnotbeencompletelydelineated.Thisstudywas
undertakentoinvestigatetheeﬀectsofdiﬀerentdosesofSEB,
LPS, and SEB plus LPS on the cytokine response and survival
of mice exposed to these bacterial products.
2.MaterialsandMethods
2.1. Reagents. SEB was obtained from Toxin Technology
(Sarasota, FL). The endotoxin content of these SEB prepa-
rations was <1ng of endotoxin per mg of SEB as determined
bytheLimulusamoebocytelysategelationtest(Biowhittaker,
Frederick, MD). Escherichia coli 055:B5 LPS was purchased
from Difco Laboratories (Detroit, MI) and reconstituted in
sterile PBS. Frozen (−70◦C) aliquots of SEB and LPS were
used for all subsequent studies.
2.2. Mouse Model of Lethal Shock. Male Balb/c mice, weigh-
ing ∼20g each (7–10 weeks old), were obtained from
NCI (Frederick, MD). Mice were housed in conventional
microisolator cages with food and water freely available at all
times.SEBandLPSwereadministeredintraperitoneally(i.p.;
200μL) with a tuberculin syringe (26G–3/8 inch needle).
When SEB and LPS were used together, LPS was injected
4 hours after SEB as this was the optimal time previously
determined to cause septic shock [19, 22–24]. All injections
(0.2mL/mouse) were given i.p. and all dilutions were made
in saline. Doses of SEB used in survival experiments range
from 1 to 100μg/mouse as described in ﬁgure legends. A
single high dose of LPS (80μg/mouse) was used (n = 27).
The eﬀect of SEB alone, either 30μg/mouse (n = 20) or
100μg/mouse (n = 10) was also examined. Survival experi-
ments were conducted with the diﬀerent doses of SEB alone,
LPS alone, and varying doses of SEB and LPS in groups of
10 to 15 mice per dose. Experiments were repeated multiple
times as indicated in ﬁgures. The following combinations
of SEB plus LPS were used: SEB 1μg/mouse plus LPS
60μg/mouse(n=20),SEB1μg/mouseplusLPS80μg/mouse
(n = 63), SEB 10μg/mouse plus LPS 10μg/mouse (n
= 30), SEB 30μg/mouse plus LPS 10μg/mouse (n =
40), SEB 60μg/mouse plus LPS 10μg/mouse (n = 40),
SEB 100μg/mouse plus LPS 10μg/mouse (n = 10), SEB
30μg/mouse plus LPS 1μg/mouse (n = 25), and SEB
100μg/mouse plus LPS 1μg/mouse (n = 10). Mice exposed
to both SEB and LPS or high dose of LPS alone succumbed
to death between 20 to 141 hours with the majority (97%) of
death occurring between 21 and 70 hours after initial toxin
dose. Lethal end points were monitored twice per day for 2
weeks.Temperature-basedexperimentswereperformedwith
each animal subcutaneously implanted (6–10 days before
toxin exposure) with a Biomedic Data Systems (Seaford, DE)
transponder located on the dorsum between the shoulder
blades [24].
Animal research was conducted in compliance with the
Animal Welfare Act as well as other federal statutes and
regulations. The facility where this research was conducted
is fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International. All
eﬀorts adhered to principles stated in the Guide for Care and
Use of Laboratory Animals (National Research Council).
2.3. Cytokine and Chemokine Assays. Previous results indi-
cated that the optimal timing for serum cytokine collection
after mice were given toxins is 8 hours after SEB [19, 22,
23]. Serum from an individual mouse was collected at 8
hours and 21 hours after SEB, from anesthetized mice retro-
orbitally or by cardiac puncture. Most experimental groups
(n = 10) were repeated multiple times over a 1.5-year period.
Sera were stored at −70◦C until assay in duplicates by
ELISA. TNFα,I L - 1 ,I L - 2 ,I L - 6 ,I F N γ,M I P - 2 ,a n dM C P - 1
were measured by ELISA using cytokine-speciﬁc antibodies
and cytokine standards from R&D Systems (Minneapolis,
MN) according to instructions of the manufacturers [19, 22,
23]. A standard curve was generated for each plate using
ﬁve dilutions of cytokine standards. The detection limit for
cytokine ELISA was 10pg/mL. Background levels of each
cytokine/chemokine, all found to be negligible, were derived
from a prebleed of the same mice performed 2–4 days before
each experiment.
2.4. Statistical Analysis. Data were analyzed with the use
of SAS software, version 9.2 (Cary, NC). Diﬀerences in
cytokine/chemokine levels between treatment groups were
assessed by obtaining geometric means with 95% con-
ﬁdence intervals. Statistical comparisons of survival and
cytokine/chemokine data were performed using two-tailed
Fisher’s exact tests and analysis of variance (ANOVA),
respectively. All reported P-values are two sided, and a P
value of less than .05 was considered to indicate statistical
signiﬁcance.
3. Results
3.1. Survival Analysis of Varying Doses of SEB, LPS, and SEB
in Combination with LPS. Mice exposed to 30μg( n = 20)
or 100μg( n = 10) of SEB all survived. Exposure to 80μgL P S
alone(n =27)resultedin52%survival,signiﬁcantlydiﬀerent
from mice treated with SEB alone (P < .05) (Figure 1(a)).
S u r v i v a lr a t e so fm i c ee x p o s e dt o3 0μgS E Bp l u s1μgL P S
(n = 25) or 100μgS E Bp l u s1 μgL P S( n = 10) were 96%
and 100%, respectively, and did not diﬀer signiﬁcantly from
mice singularly treated with SEB (Figure 1(b)). Increasing
LPS10foldto10μg/mousewithvaryingdosesofSEByielded
asigniﬁcantdiﬀerenceinsurvivalratesfrommiceexposedto
SEB alone (P < .05). Mice exposed to 10μgS E B( n = 30) or
30μgS E B( n = 40), 60μgS E B( n = 40), or 100μg( n = 10)
with a constant amount of LPS (10μg) had 37%, 10%, 27%,
and 30% survival rates, respectively (Figure 1(b)). There
were no survivors when mice were exposed to 1μg/mouse
SEB and 80μg/mouse LPS (n = 63) or 1μg/mouse SEB and
60μg/mouse LPS (n = 20) (Figure 1). Increasing SEB dose
with a relatively low amount of LPS (10μg) did not aﬀect
survival rates signiﬁcantly whereas higher LPS doses (either
60 or 80μg) plus a low dose of SEB (1μg) caused completeMediators of Inﬂammation 3
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Figure 1: Survival analysis of BALB/c mice treated with (a) 1μg SEB plus 80μgL P S( n = 63), 100μg SEB plus 10μgL P S( n = 10), 100μgS E B
plus 1μgL P S( n = 10), 100μgS E B( n = 10), and 80μgL P S( n = 27). (b) 1μg SEB plus 60μgL P S( n = 20), 10μg SEB plus 10μgL P S( n = 30),
30μg SEB plus 10μgL P S( n = 40), 60μg SEB plus 10μgL P S( n = 40), 100μg SEB plus 10μgL P S( n = 10), 30μg SEB plus 1μgL P S( n = 25),
and 100μg SEB plus 1μgL P S( n = 10).
mortality. It appears that systemic shock using SEB plus LPS
combinations in this mouse model was driven to a large
extent by LPS although synergism with SEB was necessary.
3.2. Hypothermia in Nonsurvivors of Toxic Shock. In addition
to lethality as an endpoint, body temperature was also used
as a marker of systemic shock as previous studies showed
hypothermia precedes death in SEB-induced shock [24].
Figure 2showsthatmicegivenSEBalonemaintainednormal
body temperature similar to temperature of control mice
exposed to bovine serum albumin. However, mice exposed
to 1μg/mouse SEB and 80μg/mouse LPS experienced
hypothermia as early as 8 hours after SEB and temperature
continued to drop dramatically. Interestingly, mice exposed
to LPS alone (80μg/mouse) had a slight temperature drop of
2◦Cat8hoursandmoderatehypothermiawasrecordedat21
hours.As50%ofmicesurvivedinthisgroup,re-examination
of temperatures of nonsurvivors and survivors in the LPS-
treated group separately revealed that hypothermia was
experienced only in nonsurvivors (Figure 2). Thus, there
is a good correlation between lethality and hypothermia
regardless of the toxin and body temperature is an accurate
indicator of systemic shock.
3.3. Eﬀect of SEB, LPS, and Varying Doses of SEB Plus
LPS on Serum Cytokines and Chemokines. Proinﬂammatory
mediators have critical pathophysiologic eﬀects in vivo and
many of the manifestations of septic shock have been
correlated to the exaggerated release of these cytokines upon
interaction of host cells with SEB and/or LPS [1, 2, 7, 8, 12].
We and others showed that serum TNFα,I L - 1 ,I L - 6 ,a n d
IFNγ were critical in inducing lethality in murine models of
SEB-induced shock [16, 19, 23]. Here we also examined the
serum levels of these cytokines and two chemokines, MIP-2
and MCP-1, from mice exposed to varying doses of SEB plus
L P Sa sa l lm i c es u r v i v e d ,e v e na t1 0 0μgo fS E B .T w ot i m e
points,8and21hourswerechosenassomecytokinessuchas
TNFα and IL-1 are induced relatively early [19] and the later
time at 21 hours might reveal the cytokines induced later by
syngergistic eﬀects. The 21 hours time point is also the time
near the lethal end point.
We ﬁrst investigated serum cytokines levels of mice
treated with either SEB or LPS alone. SEB (100μg/mouse, n
= 10) induced high levels of IL-2 and MCP-1, 24174pg/mL
and 3103pg/mL, respectively, measured at 8 hours after SEB
(Figure 3(a)). Both of these cytokines dropped dramatically
to 272pg/mL and 6pg/mL for IL-2 and MCP-1, respectively
at 21 hours. In contrast, LPS (80μg/mouse, n = 16)
induced signiﬁcantly higher levels of IL-6, MIP-2, and MCP-
1 (4584pg/mL, 179pg/mL, 29721pg/mL) but negligible IL-
2 (2pg/mL) when compared to the SEB-treated group at
8 hours. This is not surprising as IL-2 is a T cell growth
factor mostly induced by T-cell mitogens or stimulants. At
this early time point, a 6000-fold higher IL-6 and 10-fold
higher MCP-1 were seen in the LPS-treated group when
compared to the SEB-treated group. The low level of TNFα
induced by LPS seen here was likely due to the sampling
time after LPS exposure (4 hours) as TNFα peaked 904 Mediators of Inﬂammation
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Figure 2: Temperature changes of BALB/c mice treated with 100μg
SEB, 80μgL P S ,1μg SEB plus 80μg LPS, or 100μg of bovine serum
albumin (BSA). Points represent the mean ± standard deviation
(SD) for each group (n = 10) except for survivors (80LS) and
nonsurvivors (80LNS) of mice treated with 80μgL P S .
m i n u t e st o1 2 0m i n u t e sa f t e rL P Sa n dd i s a p p e a r e dw i t h i n
6t o8h o u r s[ 24, 25]. The sampling time of 8 hours after
SEB (4 hours after LPS) was a compromise time chosen to
accommodatetheothercytokines/chemokinesthatappeared
later after TNFα.A t2 1h o u r sa f t e rt o x i ne x p o s u r e ,a l l
cytokines decreased to lower levels (>100pg/mL) except
that of IL-6 (983pg/mL) and MCP-1 (3341pg/mL) in LPS-
treated mice and 272pg/mL of IL-2 in SEB-treated mice
(Figure 3(b)).Pairwisecomparisonofmicetreatedsingularly
withSEBorLPSindicatedthelevelsofIL-6,IL-2,andMCP-1
weresigniﬁcantlydiﬀerentbetweenthetwogroupsat8hours
and IL-6 and MCP-1 remained signiﬁcantly diﬀerent at 21
hours.
We also analyzed and compared the cytokine levels
between two groups of mice treated with a constant SEB
dose of 30μgb u td i ﬀerent low LPS doses of 1μg( n = 24) or
10μg( n = 14). Figure 4(a) shows signiﬁcantly higher TNFα,
IL-6, IL-2, and MIP-2 were found in the 30μgS E Bp l u s
10μg LPS group at 8 hours. At 21 hours, signiﬁcantly higher
TNFα, IL-1, IL-6, IL-2, and MCP-1 were found in the 30μg
SEB plus 10μg LPS group compared to the 30μgS E Bp l u s
1μgL P Sg r o u p( Figure 4(b)). Thus there was a substantial
potentiation of cytokines and chemokines with the higher
LPS dose when SEB was kept constant. Pairwise comparison
ofthesetwogroupsshowedprolongedhigherlevelsofTNFα,
IL-6, and MCP-1 levels in the higher LPS dose (10μg) group.
It appears that the higher cytokine response, especially at the
later time point, was also inﬂuenced mostly by the LPS dose.
The cytokine response using a combination of vary-
ing doses of SEB with LPS, SEB 30μg/mouse plus LPS
1μg/mouse(n=24),SEB100μg/mouseplusLPS1μg/mouse
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Figure 3: Serum levels of TNFα,I L - 1 ,I L - 6 ,I F N γ, IL-2, MIP-2,
and MCP-1 at (a) 8 hours after SEB or LPS administration (b)
21 hours after SEB or LPS administration. Points represent the
geometric mean ± standard deviation (SD) for each group. SEB
group consisted of mice treated with 100μg SEB and LPS group was
treated with 80μg LPS. The “∗” indicates P < .05 between groups
treated with SEB or LPS.
(n = 10), SEB 10μg/mouse plus LPS 10μg/mouse (n =
5), SEB 30μg/mouse plus LPS 10μg/mouse (n = 14),
SEB 60μg/mouse plus LPS 10μg/mouse (n = 10), SEB
100μg/mouseplusLPS10μg/mouse(n=3),SEB1μg/mouse
plus LPS 60μg/mouse (n = 1 0 ) ,a n dS E B1 μg/mouse plus
LPS 80μg/mouse (n = 34), was also analyzed. As shown
in Figure 1, most mice survived the lower dose of LPS
(1μg/mouse) plus SEB whereas survival decreased substan-
tially with the higher LPS dose (10μg/mouse) plus various
SEB doses. ANOVA was used to analyze the various cytokine
and chemokine levels between survivors and nonsurvivors
of treatment groups exposed to both SEB and LPS. In
mice treated with both SEB and LPS, signiﬁcant diﬀerences
(P < .05) in levels of TNFα (2pg/mL in survivors versus
535pg/mL in nonsurvivors), IL-6 (2531pg/mL in survivors
versus 15325pg/mL in nonsurvivors), MIP-2 (31pg/mL inMediators of Inﬂammation 5
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Figure 4 :S e r u ml e v e l so fT N F α,I L - 1 ,I L - 6 ,I F N γ, IL-2, MIP-2, and
MCP-1 of mice treated with 30μgS E B+1μgL P So r3 0μgS E B+
10μg LPS (a) 8 hours after SEB administration (b) 21 hours after
SEB administration. Values represent the geometric mean ± SD for
each group. The “∗” indicates P < .05 when comparing the two
groups.
survivors versus 945pg/mL in nonsurvivors), and MCP-
1 (9672pg/mL in survivors versus 50142pg/mL in non-
survivors) measured at 8 hours after SEB administration
(Figure 5(a)). In addition to these cytokines/chemokines,
signiﬁcant higher levels of IFNγ (84pg/mL in survivors
versus 1262pg/mL in nonsurvivors) and IL-2 (8pg/mL in
survivors versus 385pg/mL in nonsurvivors) were observed
21 hours after SEB administration (Figure 5(b)). More
importantly, IL-6, MIP-2, and MCP-1 levels remained
high at the later time point in nonsurvivors. Overall, this
analysis of cytokine levels by survival status agreed with
the data from nonsurvivors and survivors of all groups of
mice treated singularly with SEB, LPS, or both SEB and
LPS.
4. Discussion
The exaggerated systemic response to SEB is similar to LPS
where excessive proinﬂammatory cytokine release causes
increase in vascular permeability, cell adhesion, and coag-
ulation [2, 12]. Either SEB or LPS alone induce these
proinﬂammatory mediators and it is not clear whether
there is a threshold level of these mediators above which
either singularly or in combination they can trigger shock.
LPS naturally synergizes with superantigens to induce the
proinﬂammatory cascade culminating in shock. Moreover,
the cytokines, TNFα,I L - 1 ,a n dI F N γ induced by either SEB
or LPS also synergizes with each other to promote inﬂam-
mation [26]. In this study we investigated the contribution
of the cytokines, TNFα,I L - 1 ,I L - 6 ,I F N γ, and IL-2, and
chemokines, MIP-2 and MCP-1, to lethal shock in mice
exposed to SEB or LPS and their combination. Our survival
analysis indicated that increasing LPS dose had more eﬀect
in inﬂuencing mortality than SEB dose with SEB plus LPS-
induced shock. The cytokine data also showed that a higher
LPS dose with a constant SEB dose was responsible for
signiﬁcantly higher serum levels of TNFα, IL-1, IL-6, IL-
2, and MCP-1. Clearly, the mortality data paralleled the
cytokine data indicating synergistic action of SEB and LPS,
withLPSasthedominantfactorinthismousemodeloftoxic
shock.
Cytokines are intracellular signaling proteins released
from virtually all nucleated cells that regulate cell diﬀeren-
tiation, proliferation, and inﬂammation [26]. Dysregulation
of cytokine production has been associated with a variety
of diseases, including autoimmune disorders, infectious
diseases, cardiovascular diseases, asthma, and allergy. We
examined the cytokines TNFα,I L - 1 ,I L - 6 ,I F N γ,a n dI L - 2
as they are present in high levels in various animal models
of shock [16–19]. The chemokines are chemoattractants
p r o d u c e db ym a n yc e l lt y p e sa n da r ep o t e n tm o l e c u l e s
involved in host defense as they direct leukocyte migration to
sites of infection and injury [26]. We chose to examine two
prototypical chemokines, MIP-2 and MCP-1, in this study as
they inﬂuence leukocyte migration in various animal models
of infectious diseases and inﬂammation [27].
In this study, we showed that signiﬁcantly diﬀerent levels
of TNFα (95-fold, P < .0001), IL-6 (32-fold, P < .0001),
MIP-2 (15-fold, P < .0001), and MCP-1 (7-fold, P < .0001)
were present in survivors and nonsurvivors among SEB, LPS,
and SEB plus LPS treated animals early after toxin exposure.
Most notably, a near 2 log higher level of serum TNFα was
seen early in nonsurvivors. Signiﬁcantly elevated IFNγ (18-
fold, P < .0001) and IL-2 (31-fold, P < .0001) occurred later,
21 hours after toxin exposure, in nonsurvivors compared to
survivors in all treatment groups. At this later time point,
sustained elevated IL-6 (220-fold, P < .0001), MIP-2 (15-
fold, P < .0001), and MCP-1 (107-fold, P < .0001) were
also observed in nonsurvivors. The synergistic action of
SEB and LPS promotes moderate level of TNFα early and
prolongs the release of IL-6, IFNγ, IL-2, MIP-2, and MCP-1
in nonsurvivors. The disordered immune response based on
theexaggeratedreleaseofacombinationofproinﬂammatory
cytokines and chemokines early (TNFα, IL-6, MIP-2, and6 Mediators of Inﬂammation
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Figure 5 :S e r u ml e v e l so fT N F α,I L - 1 ,I L - 6 ,I F N γ, IL-2, MIP-2, and MCP-1 of mice treated with SEB + LPS (a) 8 hours after SEB
administration (b) 21 hours after SEB administration by survival status. Points represent the geometric mean ± standard deviation (SD)
for survivors and nonsurvivors of mice treated with SEB + LPS. SEB + LPS group consisted of mice treated with 1μgS E B+8 0μgL P S ,1μg
SEB + 60μgL P S ,1 0μgS E B+1 0μgL P S ,3 0μgS E B+1 0μgL P S ,6 0μgS E B+1 0μg LPS, 100μgS E B+1 0μgL P S ,3 0μgS E B+1μgL P S ,a n d
100μgS E B+1μg LPS. Values represent the geometric mean ± SD for each group. The “∗” indicates P < .05 when survivors were compared
with nonsurvivors of toxic shock.
MCP-1) at 8 hours, followed by signiﬁcant increase of IFNγ
and the substained high levels of IL-6, MIP-2, and MCP-1
later appear to be critical in inﬂuencing survival in shock.
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